<ul><li>Hy2Care, a spin-off company of the MIRA Institute of the University of Twente, secures €4.5M funding for US clinical trial and commercial expansion.</li><li>Half of the funding is from the European Innovation Council (EIC) Fund investment, with the rest from existing shareholders including Brightlands Venture Partners and new investors like LIOF.</li><li>The funding will aid in finalizing preparations for the upcoming US clinical trial of CartRevive hydrogel implant for cartilage repair and support commercial rollout in global markets.</li><li>Hy2Care's CEO, Leo Smit, notes that the financing will propel the company into launching the U.S. clinical trial and establishing commercialization foundations in EMEA.</li></ul>

Dutch-based Hy2Care raises €4.5M from EIC, others for US clinical trial and commecial expansion

Discover more